Mechanisms of allergy and clinical immunologyAnti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels
Section snippets
Inclusion and exclusion criteria
Twenty-five subjects (13 male and 12 female subjects 18-57 years of age) were enrolled in an open-label phase I/II trial designed to assess the safety of mepolizumab and to delineate the effect of neutralizing endogenous IL-5 activity in patients with eosinophilic disorders, as previously described.18, 20
Subject characteristics
Of the 25 subjects enrolled, 18 were diagnosed with a diverse set of HESs, as defined by a recent workshop (Table I).22 Six subjects were diagnosed with EE. Of these subjects, 4 subjects with
Effect of anti–IL-5 therapy (mepolizumab) on peripheral blood eosinophil levels
Subjects (Table I) were observed, stabilized, or both for 8 weeks, subsequently infused with 3 doses of intravenous mepolizumab at 4-week intervals (weeks 8, 12, and 16), and monitored thereafter for an additional 12 weeks (Fig 1, A). Mepolizumab therapy was generally well tolerated (Table I).
During the first 8 weeks, the mean eosinophil level ranged from 1183 ± 2073 cells/mm3 at baseline to 1400 ± 2179 cells/mm3 (mean ± SD, P = .15). After mepolizumab therapy, a marked and sustained decrease
Discussion
Eosinophilic disorders are a heterogeneous group of diseases characterized by blood eosinophilia, tissue eosinophilia, or both with end organ damage. Current therapies for these disorders are often unsatisfactory because of their inefficiency to abate the eosinophilia, their toxicity, or both. Herein we report the immunologic and hematologic effects of anti–IL-5 (mepolizumab) in 25 patients with diverse eosinophilic disorders. Our findings establish that (1) mepolizumab is effective in
References (35)
- et al.
Eosinophil trafficking in allergy and asthma
J Allergy Clin Immunol
(2007) - et al.
Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia
Blood
(1990) Eosinophilic gastrointestinal disorders (EGID)
J Allergy Clin Immunol
(2004)- et al.
Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response
J Allergy Clin Immunol
(2001) - et al.
In vivo administration of antibody to interleukin-5 inhibits increased generation of eosinophils and their progenitors in bone marrow of parasitized mice
Blood
(1990) - et al.
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
Lancet
(2000) - et al.
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
J Allergy Clin Immunol
(2004) - et al.
Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
Blood
(2004) - et al.
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis
J Allergy Clin Immunol
(2006) - et al.
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report
J Allergy Clin Immunol
(2006)
Receptor internalization is required for eotaxin-induced responses in human eosinophils
J Allergy Clin Immunol
Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T-lymphocytes and U-937 cells
Exp Cell Res
Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members
Blood
Interleukin-5, eosinophils, and disease
Blood
Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit
Blood
Schistosoma mansoni infection in eosinophil lineage-ablated mice
Blood
Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700
J Allergy Clin Immunol
Cited by (133)
Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape
2023, Survey of OphthalmologyMepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
2022, Journal of Allergy and Clinical Immunology: In PracticeClinical effects and immune modulation of biologics in asthma
2021, Respiratory InvestigationEfficacy of dupilumab and biomarkers for systemic corticosteroid naïve allergic bronchopulmonary mycosis
2021, Allergology InternationalEfficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
2020, Journal of Allergy and Clinical Immunology
Supported by Food and Drug Administration grant no. FD-R 002313, the Burroughs Wellcome Fund, the CURED (Campaign Urging Research for Eosinophilic Diseases) Foundation, and the Buckeye Foundation. We are grateful to the Translational Research Office at CCHMC for their assistance and the General Clinical Research Center at CCHMC (supported by USPHS GCRC grant no. M01 RR 08084 from the National Center for Research Resources, National Institutes of Health). Miguel L. Stein is a recipient of a fellowship from the American Physicians Fellowship for Medicine in Israel.
Disclosure of potential conflict of interest: A. H. Assa'ad has consulting arrangements with and has received research support from GlaxoSmithKline and has served as an expert witness in food allergy and anaphylaxis litigation. M. E. Rothenberg has consulting arrangements with Merck, Ception Therapeutics, and Medacorp; is on the speakers' bureau for Merck; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, Ception Therapeutics, and Merck; and is on the advisory board for the National Institutes of Health and the American Partnership for Eosinophilic Disorders. The rest of the authors have declared that they have no conflict of interest.